http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Atypical depression: a comprehensive review.
Pae, Chi-Un,Tharwani, Haresh,Marks, David M,Masand, Prakash S,Patkar, Ashwin A Adis International 2009 CNS drugs Vol.23 No.12
<P>Despite several decades of research, the characteristics distinguishing atypical depression from other depressive subtypes remain ambiguous. Multiple lines of evidence support the designation of atypical depression as a scientifically and clinically relevant subtype, including differences in hormonal responses, brain laterality, psychological profile and psychiatric co-morbidity and differential treatment response. The evolution of the diagnostic criteria for atypical depression has led to the designation of mood reactivity as the cardinal feature, and the research supporting this conclusion is reviewed. This paper also reviews the evidence for the drug treatment of atypical depression, with a particular focus on research related to the superior efficacy of monoamine oxidase inhibitors (MAOIs) compared with tricyclic antidepressants (TCAs). Data relevant to the efficacy of newer antidepressants, including selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline (norepinephrine) reuptake inhibitors, transdermal selegiline and other new agents for atypical depression, are discussed. In summary, the diagnostic reliability and validity of atypical depression still remain elusive and open to further evolution. Currently available findings suggest that atypical depression has preferential response to MAOIs over TCAs. More data are required to determine the efficacy of newer agents relative to MAOIs and TCAs, although limited studies have shown a non-inferior efficacy and better tolerability of newer agents such as SSRIs compared with those of MAOIs and TCAs. Finally, future directions for research include further refinement of the diagnostic criteria for atypical depression, and clarification of the role of newer antidepressants in the treatment of this subtype with evidence from randomized, controlled trials.</P>
Oh, Yongtaek,Park, Sung Won,Chun, Sung-Min,Lim, Namkyoo,Ahn, Ki Sup,Ka, Jong-Ok,Jin, Dong-Kyu,Han, Byoung-Don Adis International 2009 Molecular diagnosis & therapy Vol.13 No.6
<P>Congenital adrenal hyperplasia (CAH) is an autosomal recessive disease caused by mutations in the CYP21A2 gene, which codes for steroid 21-hydroxylase. More than 90% of patients with CAH have mutations in CYP21A2 or have large deletions in the RCCX module on chromosome 6p21.3, which also includes the pseudogene CYP21A1P. Genotyping of CYP21A2 is required for diagnosis of CAH, but current genotyping methods, such as direct sequencing, allele-specific PCR amplification, or PCR amplification and restriction fragment length polymorphism (PCR-RFLP) still need further improvements to reduce test time and cost.</P>
Yi, SoJeong,Kim, Sung Eun,Park, Min-Kyu,Yoon, Seo Hyun,Cho, Joo-Youn,Lim, Kyoung Soo,Shin, Sang-Goo,Jang, In-Jin,Yu, Kyung-Sang Adis International 2012 BioDrugs Vol.26 No.3
<P>HD203 is a biosimilar of etanercept, a fusion protein of the ligand-binding portion of the human tumor necrosis factor receptor II linked to the Fc portion of human immunoglobulin G1. Since HD203 is under clinical development, this study was conducted to compare the pharmacokinetics of HD203 with Enbrel®, the first marketed etanercept.</P>
Han, HyeKyung,Lee, Jongtae,Shin, Donghoon,Shin, Kwang-Hee,Jeon, Hyewon,Lim, Kyoung Soo,Yoon, Seo Hyun,Shin, Sang-Goo,Jang, In-Jin,Cho, Joo-Youn,Yu, Kyung-Sang Adis International 2014 Clinical drug investigation Vol.34 No.6
<P>GC1113, a hybrid Fc-fused erythropoietin, is a novel erythropoiesis-stimulating agent that is expected to have an extended duration of action. The preclinical data showed that the hemoglobin increase lasted longer following GC1113 administration than it did following the administration of darbepoetin alfa (NESP?). This study aimed to investigate the pharmacodynamic and pharmacokinetic characteristics and tolerability profiles of GC1113 in humans after single intravenous or subcutaneous administration and to compare the results with those for darbepoetin alfa.</P>
Shin, Dongseong,Cho, Young Min,Lee, SeungHwan,Lim, Kyoung Soo,Kim, Jeong-Ae,Ahn, Ji-Yung,Cho, Joo-Youn,Lee, Howard,Jang, In-Jin,Yu, Kyung-Sang Adis International 2014 Clinical drug investigation Vol.34 No.6
<P>Gemigliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes mellitus. This study evaluated possible pharmacodynamic and pharmacokinetic interactions between gemigliptin and metformin and investigated their tolerability.</P>
Bae, Soo Kyung,Kim, Soo-Hwan,Lee, Hae Won,Seong, Sook Jin,Shin, Su-Yeon,Lee, Sang Hun,Lim, Mi-Sun,Yoon, Young-Ran,Lee, Hye Jung Adis International 2012 Clinical drug investigation Vol.32 No.2
<P>A new controlled-release formulation of aceclofenac 200?mg (Clanza CR?) developed by Korea United Pharm., Inc., South Korea, for once-daily (od) dosing provides biphasic aceclofenac release consisting of immediate release of 85?mg followed by sustained release of 115?mg. Food has been known to affect the rate and extent of absorption of several drugs, in both immediate-release and controlled-release formulations.</P>
Ahn, Li Young,Kim, Sung Eun,Yi, SoJeong,Dingemanse, Jasper,Lim, Kyoung Soo,Jang, In-Jin,Yu, Kyung-Sang Adis International 2014 American journal of cardiovascular drugs Vol.14 No.5
<P>Macitentan is a novel dual endothelin (ET)-1 receptor antagonist to be used in patients with pulmonary arterial hypertension. This study aimed to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of macitentan after administration of multiple doses to healthy Korean male subjects.</P>
Park, Min Kyu,Kim, Tae-Eun,Kim, JaeWoo,Kim, Chin,Yoon, Seo Hyun,Cho, Joo-Youn,Jang, In-Jin,Yu, Kyung-Sang,Lim, Kyoung Soo Adis International 2014 Clinical drug investigation Vol.34 No.7
<P>Lobeglitazone is a recently approved peroxisome proliferator-activated receptor-γ agonist for the treatment of type 2 diabetes mellitus in Korea. The purpose of this study was to investigate the pharmaco kinetic properties of lobeglitazone in healthy females and to compare these with historical data in healthy males.</P>
Kim, Bo-Hyung,Kim, Jung-Ryul,Lim, Kyoung Soo,Shin, Hyun-Suk,Yoon, Seo Hyun,Cho, Joo-Youn,Jang, In-Jin,Shin, Sang-Goo,Yu, Kyung-Sang Adis International 2012 Clinical drug investigation Vol.32 No.12
<P>Clopidogrel selectively inhibits platelet aggregation. Clopidogrel bisulfate (Plavix(?)) was first developed for atherothrombosis prevention and is commonly prescribed for this indication. A new clopidogrel formulation, clopidogrel besylate (KOVIX(?)), has recently been developed.</P>